Eli Lilly's stock got a boost today after the pharmeceutical maker said the FDA approved Gemzar, its drug for use in patients with recurring ovarian cancer despite objections from an expert medical panel that voted 9-2 against recommending approval of Gemzar for ovarian cancer.
The panel questioned Lilly's trial data and the way the company conducted a 356-person clinical study.
More.
No comments:
Post a Comment